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Left Bundle Branch
Block After Transcatheter
Aortic Valve Implantation
Inconsequential or a
Clinically Important Endpoint?*
Antonio Colombo, MD, Azeem Latib, MD
Milan, Italy
The close proximity of the aortic valve complex to the His
bundle makes the intraventricular conduction tissue suscep-
tible to damage during transcatheter aortic valve implanta-
tion (TAVI) (1,2). New-onset left bundle branch block
(LBBB) is the most frequently observed conduction abnor-
mality, which is explained by the very superficial location of
the left bundle branch in the uppermost part of the leftward
ventricular septum. The left bundle branch may be easily
traumatized by manipulation of catheters or stiff wires,
balloon valvuloplasty, valve implantation, or post-dilatation,
and more than one-half of the conduction abnormalities
during TAVI have been reported to occur prior to valve
implantation (3).
See page 1743
The pathology of these conduction disturbances may be
transient inflammation, edema, ischemia, or mechanical
stress, which may explain why many recover. There are
limited data on the clinical consequences of new-onset
LBBB after TAVI. Indeed, clinical dilemmas often faced by
physicians managing patients post-TAVI are whether the
new-onset LBBB could progress to complete heart block
(CHB) and whether LBBB negatively affects left ventricular
(LV) function and prognosis. With regard to the latter,
LBBB has been identified as a predictor of poorer clinical
outcomes, both in the surgical literature (after surgical aortic
valve replacement) (4) and in the general cardiology litera-
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underestimated the prognostic significance of new-onset
LBBB after TAVI.
In this issue of the Journal, Urena et al. (6) report the
“true” incidence, predictors, and clinical consequences of
persistent LBBB after the implantation of the balloon-
expandable valve (Sapien and Sapien XT, Edwards Life-
sciences LLC, Irvine, California) in 202 consecutive pa-
tients. In interpreting their results, particularly in the
context of other published literature, it is important to note
that the investigators studied a “clean” population and
excluded patients with baseline ventricular conduction dis-
turbances or a history of permanent pacemaker implantation
(PPI). The main findings were:
• New-onset LBBB occurred in 30.2% of patients im-
mediately after Edwards implantation and had re-
solved in 37.7% at discharge and 57.3% at 1-year
follow-up.
• Longer baseline QRS duration and a more ventricular
positioning of the prosthesis predicted persistent
LBBB.
• LBBB at discharge was associated with higher risks for
syncope, CHB, and PPI (20% vs. 0.7%) but not
sudden death or mortality, at 1-year follow-up.
• Persistent LBBB was associated with a decrease of
4.75  8.02% in LV ejection fraction (LVEF) and a
poorer New York Heart Association functional class at
1-year follow-up.
This represents one of the largest published studies to
pecifically evaluate the incidence, progression, predictors,
nd clinical significance of new-onset LBBB after TAVI.
s demonstrated in Table 1, the incidence of new-onset
BBB (if calculated in a similar way by excluding patients
ith pre-existing LBBB, right branch bundle block, and
PI) varies considerably, from 25% to 85% (mean: 60.4%
95% confidence interval (CI): 56.9% to 63.9%] in 738
atients from 11 studies) (1–3,7–14) after implantation of
he self-expandable CoreValve (Medtronic Inc, Minneapo-
is, Minnesota) and from 8% to 30% (mean: 21.9% [95% CI:
8.3% to 26.0%] in 438 patients from 5 studies) (6,14–17)
fter the implantation of a balloon-expandable valve. With
egard to the time course of LBBB, this conduction distur-
ance usually occurs during TAVI but can occur afterwards
n 2% to 8% (18, 19). It is reversible by discharge in up to
ne-half of patients treated with a self-expandable valve and
n about one-third of patients treated with a balloon-
xpandable valve. These findings suggest that the injury to
he left bundle branch sometimes may be transient. The fact
hat the incidence of LBBB is greater following implanta-
ion of the self-expandable valve may be a consequence of
he fact that this valve type tends to land deep in the LV
utflow tract more frequently compared to the balloon-
xpandable valve. Considering the close anatomic relation-
hip between the annulus and left bundle branch, it is not
-expan
tation;
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LBBB After TAVI October 30, 2012:1753–5surprising that the depth of valve implantation has been the
most frequently identified predictor of LBBB in patients
with either of the 2 prostheses (2,6,12,14). Although
speculative, high valve implantation may reduce the risk for
LBBB. It would be interesting to study whether implanta-
tion in a high position is associated with a low occurrence of
LBBB even with the self-expandable valve. The other
predictor identified in this study, longer baseline QRS, was
probably a marker of underlying degenerative conduction
system disease in this elderly population.
The present study provides us with important data to
respond to 2 clinically important questions.
First, could new-onset LBBB progress to CHB? Based
on the present study, new-onset LBBB was the only factor
associated with PPI following TAVI (21.3% of patients
overall). A clinically relevant but unappreciated finding was
that 1 in 5 patients discharged with LBBB required PPI
during follow-up. Similarly, 20.3% (95% CI: 16.4% to
24.9%) of patients with new-onset LBBB after the implan-
tation of a self-expandable valve may require PPI. This
information is original because “new-onset LBBB” has not
been previously identified as a predictor for CHB or PPI in
Summarizing Incidence Rates,* Time Course, and Requirementsfor Permanent Paci g in Patients With New-Onset LBBB Aft r TAVITable 1 Summarizi g Incidence Rates,* Tim Course, and Reqfor Permanent Pacing in Patients With New-Onset LBB
Valve Type/Study
First Author (Ref. #) N Excluded
New-Onset LBBB
Immediately
After TAVI
Self-expandable valve†
Khawaja (1) 243 58 — 56
Piazza (2) 39 9 — 53
Nuis (3) 65 12 67.9 (36/53) 75
Jilaihawi (7) 30 8 —
Fraccaro (8) 64 17 — 59
Guetta (9) 70 28 — 78
Tzikas (10) 27 1 — 53
Chorianopulos (11) 130 27 77.7 (80/103) 84
Calvi (12) 162 23 54.7 (76/139) 56
Munoz-Garcia (13) 61 37 —
Balloon-expandable valve —
Urena (6) 202 0 28.2 (57/202) 30
Gutiérrez (15) 33 5 — 21
Godin (16) 69 17 — 17
Sinhal (17) 106 22 — 8
Both types included
Aktug (14)
Self-expandable 72 5 — 40
Balloon-expandable 82 10 — 18
Roten (18) 41/26¶ 14/10¶ 34.9 (15/43) 41
Erkapic (19) 36/14¶ 12 — 52
Values are % (n/N). *Incidence rates may differ from those in the original articles, as they were calc
(if not already excluded by the investigators), when these data were reported. †Trademark: Cor
follow-up, and overall. Trademark: Sapien (Edwards Lifesciences LLC, Irvine, California). ¶For self
LBBB  left bundle branch block; N/A  not available; PPI  permanent pacemaker implanother studies, probably because these studies included onlybaseline and procedural variables in the predictive multivar-
iate models.
Second, can and how does new-onset LBBB affect
long-term outcomes? Urena et al. (6) reported that new-
onset LBBB worsens LVEF and functional status, which
may seem provocative at first glance. However, LBBB has
been shown to be associated with deterioration of LV
systolic and diastolic function, worsening heart failure and
has been identified as a predictor of increased mortality in
patients with isolated LBBB as well as those with structural
heart disease. Indeed, the sicker the patient, the greater the
impact of this conduction disturbance on adverse outcomes
(5,20). Zannad et al. (5) eloquently summarized the patho-
physiologic mechanisms as: LBBB, intraventricular asyn-
chrony, reduced pump function, neurohormonal activation,
asymmetric hypertrophy, and dilatation, followed by dete-
riorating LV function and emerging heart failure. Another
factor that provides further evidence of the negative effects
of LBBB and that is of particular importance to TAVI
patients is the impact of right ventricular (RV) pacing,
which shares common features with the depolarization and
mechanical activity observed in LBBB. The MOST (Mode
ents
er TAVI
nset
B
pital
Resolved at
Discharge
Persistent
LBBB at
Discharge
Persistent
LBBB at
1 Yr
PPI After
New-Onset
LBBB
5/185) N/A N/A N/A 32.4 (34/105)
/30) 56.3 (9/16) 23.3 (7/30)‡ N/A N/A
/53) 30 (12/40) 49.1 (26/53) N/A 5 (2/40)
/22) N/A N/A N/A 0
/47) 10.7 (3/28) 53.2 (25/47) N/A N/A
/42) 27.3 (9/33)‡ 38.1 (16/42) N/A 24.2 (8/33)
/26) N/A 53.8 (14/26) N/A N/A
/103) 6.3 (5) 79.6 (82/103) N/A 13.8 (12/87)
/139) 6.6 (5) 46 (64/139) N/A 12.7 (10/79);
6.3 (4/64);
17.7 (14/79)§
24) 0 25 (6/24) N/A
/202) 37.7 (23/61) 12.4 (25/202) 36 (9/25) 13.1 (8/61);
20 (5/25);
21.3 (13/61)§
28) 33.3 (2/6) 13.3 (4/30) 3.3 (1/30)‡ 0
52) 66.7 (6/9)‡ 5.8 (3/52)‡ N/A 11.1 (1/9)
84) 42.9 (3/7) 4.8 (4/84) N/A 0
N/A 17.5 (7/40)
/67) 55.6 (15/27) 17.9 (12/67) — —
/72) 46.2 (6/13) 9.7 (7/72)‡ — —
/43)‡ 11.1 (2/18)‡ 23.3 (10/43)‡ N/A 33.3 (6/18)
/38) N/A N/A N/A N/A
ith the exclusion of patients with pre-existing LBBB, right branch bundle block, or PPI implantation
(Medtronic Inc, Minneapolis, Minnesota). ‡Only 1-month data available. §Values for in-hospital,
dable and balloon-expandable valves, respectively.
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was a significant association between RV pacing and the risk
for hospitalization for heart failure in patients with normal
and depressed LVEF, respectively. Thus, it is not surprising
that LBBB may be deleterious in patients with TAVI who,
by definition, have structural heart disease. Finally, it should
be remembered that restoration of the ventricular activation
sequence by cardiac resynchronization therapy opposes the
various mechanisms that lead to ventricular dilation and
ventricular remodeling.
The main limitation of the current study was the sample
size and that it did not provide information on predicting
which patients with new-onset LBBB will develop CHB or
have worsening LV function and benefit from preventative
therapy. If these findings are confirmed in larger series, the
practical message is clear: Irrespective of the device im-
planted, we should avoid positioning the aortic prosthesis
too ventricularly. Patients with new-onset LBBB post-
TAVI should be kept on continuous electrocardiographic
monitoring while in-hospital, and those discharged with
persistent LBBB should have regular Holter monitoring. In
these editors’ opinion, there are certain subgroups of pa-
tients with persistent LBBB or RV pacing post-TAVI who
should be closely monitored and even considered for cardiac
resynchronization therapy if other causes, such as prosthesis
malfunction, paravalvular leak, or coronary ischemia, have
been excluded. These patients include those with pre-TAVI
LV dysfunction without improvement in LVEF post-
TAVI, those who continue to have symptomatic heart
failure post-TAVI, and those with worsening LVEF on
serial echocardiography.
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